Mark R. Lackner

8.1k total citations
82 papers, 4.4k citations indexed

About

Mark R. Lackner is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Mark R. Lackner has authored 82 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 30 papers in Oncology and 30 papers in Cancer Research. Recurrent topics in Mark R. Lackner's work include Cancer Genomics and Diagnostics (23 papers), PI3K/AKT/mTOR signaling in cancer (20 papers) and Lung Cancer Treatments and Mutations (12 papers). Mark R. Lackner is often cited by papers focused on Cancer Genomics and Diagnostics (23 papers), PI3K/AKT/mTOR signaling in cancer (20 papers) and Lung Cancer Treatments and Mutations (12 papers). Mark R. Lackner collaborates with scholars based in United States, France and United Kingdom. Mark R. Lackner's co-authors include Lukas C. Amler, Carol O’Brien, Jill M. Spoerke, Stuart K. Kim, Garret M. Hampton, Elizabeth A. Punnoose, Heidi Savage, Timothy R. Wilson, Lori S. Friedman and Jiping Zha and has published in prestigious journals such as Cell, Nature Medicine and Nature Communications.

In The Last Decade

Mark R. Lackner

80 papers receiving 4.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark R. Lackner United States	32	2.6k	1.8k	1.5k	988	449	82	4.4k
Paolo Nucíforo Spain	42	4.1k 1.6×	3.4k 1.9×	1.8k 1.2×	1.2k 1.2×	516 1.1×	175	7.3k
Igor Garkavtsev United States	25	2.9k 1.1×	1.2k 0.7×	1.2k 0.7×	388 0.4×	135 0.3×	32	4.1k
Spencer J. Collis United Kingdom	25	2.5k 1.0×	742 0.4×	717 0.5×	448 0.5×	103 0.2×	51	3.3k
Caterina Nardella United States	19	3.1k 1.2×	1.2k 0.7×	864 0.6×	896 0.9×	305 0.7×	26	4.2k
Marta Pàez‐Ribes United Kingdom	15	1.9k 0.7×	1000 0.6×	1.1k 0.7×	452 0.5×	151 0.3×	18	3.2k
Nicholas A. Willis United States	18	3.7k 1.4×	2.3k 1.3×	998 0.6×	721 0.7×	267 0.6×	37	5.4k
Patrick W.B. Derksen Netherlands	36	3.2k 1.2×	2.4k 1.3×	926 0.6×	342 0.3×	471 1.0×	70	4.9k
Kim L. Mercer United States	10	2.6k 1.0×	1.6k 0.9×	737 0.5×	532 0.5×	222 0.5×	15	3.9k
Frank Stegmeier United States	23	3.7k 1.5×	888 0.5×	702 0.5×	666 0.7×	242 0.5×	34	4.7k
Anthony N. Karnezis United States	41	4.2k 1.6×	2.4k 1.3×	1.5k 1.0×	750 0.8×	1.1k 2.5×	90	7.9k

Countries citing papers authored by Mark R. Lackner

Since Specialization

Citations

This map shows the geographic impact of Mark R. Lackner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Lackner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Lackner more than expected).

Fields of papers citing papers by Mark R. Lackner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Lackner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Lackner. The network helps show where Mark R. Lackner may publish in the future.

Co-authorship network of co-authors of Mark R. Lackner

This figure shows the co-authorship network connecting the top 25 collaborators of Mark R. Lackner. A scholar is included among the top collaborators of Mark R. Lackner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark R. Lackner. Mark R. Lackner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wagle, Marie-Claire, Joseph Castillo, Shrividhya Srinivasan, et al.. (2020). Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer. Cancer Immunology Research. 8(7). 844–850. 6 indexed citations

Chen, Xiaoji, Ching‐Wei Chang, Jill M. Spoerke, et al.. (2019). Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort. Clinical Cancer Research. 25(7). 2254–2263. 54 indexed citations

Piskol, Robert, Ling Huw, Ismail Sergin, et al.. (2019). A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer. Clinical Cancer Research. 25(14). 4431–4442. 40 indexed citations

Moore, Heather M., Heidi Savage, Carol O’Brien, et al.. (2019). Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. Molecular Cancer Therapeutics. 19(1). 292–303. 8 indexed citations

Wilson, Timothy R., Akshata R. Udyavar, Ching‐Wei Chang, et al.. (2018). Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. Molecular Cancer Research. 17(1). 97–108. 15 indexed citations

Nakanishi, Yoshito, Kimberly Walter, Jill M. Spoerke, et al.. (2016). Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β. Cancer Research. 76(5). 1193–1203. 55 indexed citations

Ryner, Lisa, Yinghui Guan, Ron Firestein, et al.. (2015). Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. Clinical Cancer Research. 21(13). 2941–2951. 86 indexed citations

Stern, Howard M., Humphrey Gardner, Tomasz Burzykowski, et al.. (2015). PTEN Loss Is Associated with Worse Outcome in HER2 -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clinical Cancer Research. 21(9). 2065–2074. 57 indexed citations

O’Shaughnessy, Joyce, Hartmut Koeppen, Yuanyuan Xiao, et al.. (2015). Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clinical Cancer Research. 21(19). 4305–4311. 37 indexed citations

10.

Bourgon, Richard, Shan Lu, Yibing Yan, et al.. (2014). High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing. Clinical Cancer Research. 20(8). 2080–2091. 52 indexed citations

11.

Wilson, Timothy R., Yuanyuan Xiao, Jill M. Spoerke, et al.. (2014). Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples. Breast Cancer Research and Treatment. 148(2). 315–325. 21 indexed citations

12.

Penuel, Elicia, Congfen Li, Luciana Burton, et al.. (2013). HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 12(6). 1122–1130. 20 indexed citations

13.

Punnoose, Elizabeth A., Siminder Atwal, Weiqun Liu, et al.. (2012). Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib. Clinical Cancer Research. 18(8). 2391–2401. 341 indexed citations

14.

Spoerke, Jill M., Carol O’Brien, Ling Huw, et al.. (2012). Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models. Clinical Cancer Research. 18(24). 6771–6783. 149 indexed citations

15.

Hatzivassiliou, Georgia, Bonnie Liu, Carol O’Brien, et al.. (2012). ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors. Molecular Cancer Therapeutics. 11(5). 1143–1154. 155 indexed citations

16.

Hoeflich, Klaus P., Carol O’Brien, Zachary Boyd, et al.. (2009). In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models. Clinical Cancer Research. 15(14). 4649–4664. 385 indexed citations

17.

Zha, Jiping, Carol O’Brien, Heidi Savage, et al.. (2009). Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Molecular Cancer Therapeutics. 8(8). 2110–2121. 66 indexed citations

18.

Hu, Xiaolan, Howard M. Stern, Lin Ge, et al.. (2009). Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes. Molecular Cancer Research. 7(4). 511–522. 177 indexed citations

19.

Hoeflich, Klaus P., Sylvia Herter, Janet Tien, et al.. (2009). Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression. Cancer Research. 69(7). 3042–3051. 144 indexed citations

20.

Boyd, Zachary, Qun Wu, Carol O’Brien, et al.. (2008). Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Molecular Cancer Therapeutics. 7(12). 3695–3706. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact